The case for & against
Bull & Bear analysis
Jaguar Health Inc. (NASDAQ: JAGX) is a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics for the treatment of gastrointestinal disorders. The company is pioneering treatments for conditions such as Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF). JAGX operates within the broader theme of innovative healthcare solutions tailored to rare diseases, positioning itself in a specialized niche that is gaining attention due to increasing healthcare needs and limited therapeutic options.
Bull says
- ↑Crofelemer reduced parenteral support by 48% in MVID, 40% in SBS-IF
- ↑NDA filing for MVID indication expected by mid-2027
- ↑84% of past Bollinger Band breakouts saw price gains
- ↑Liquidity score of 2.28 indicates ample financial flexibility
- ↑Book-to-price ratio ~0.34 suggests potential undervaluation
- ↑Strong momentum indicators point to potential upside moves
Bear says
- ↓Earnings yield at –2.43% signals unprofitable operations
- ↓Negative profitability impedes sustainable cash generation
- ↓High volatility indicates stock-price instability
- ↓$40 M equity line risks significant share dilution
- ↓Analysts have lowered earnings expectations, dampening outlook
- ↓Negative revisions and profitability trends raise performance concerns
Investment themes with JAGX
Drug development driving global healthcare solutions
Stocks with highest short interest
Earnings Call · Q1 2025 · Mgmt. Guidance
Transcript signals
Bull points
- This is in contrast to dispensed prescriptions for Mitessi, Crofilamer, which I am pleased to announce increased in the first quarter of 2025 versus the first quarter of 2024 by approximately 2%. This is an indication of increased demand and that more patients are receiving treatment for HIV-related diarrhea from Mitessi.
- The initial proof of concept results that we issued on April 30th showed that crofilomer reduced TPN in the first MVID patient to participate in the study by up to 27%.
- These initial results are potentially transformative for the patients and their caregiving community, it's not possible to overstate the significance of reduction in TPN.
Bear points
- The total net revenue for the company's prescription products was approximately $2.2 million in the first quarter of 2025, a decrease of approximately 6% versus the first quarter of 2024, revenue of $2.4 million, and 37% versus net fourth quarter 2024 revenue of $3.5 million.
- Loss from operations increased by 1.2 million from 8.2 million in the quarter ended March 31, 2024 to $9.4 million during the same period in 2025.
- Net loss attributable to common shareholders increased by approximately 1.2 million from 9.2 million in the quarter ended March 31, 2024 to 10.4 million in the same period in 2025.